Canine mast cell tumors: Correlation of apoptosis and proliferation markers with prognosis

Journal of Veterinary Internal Medicine

Volumn 20, Issue 1, 2006, Pages 151-158

  Scase, Timothy J ^a   Edwards, David ^a   Miller, Jodi ^a   Henley, William ^a   Smith, Ken ^a   Blunden, Anthony ^a   Murphy, Sue ^a  

^a ANIMAL HEALTH TRUST   (United Kingdom)

Author keywords

AgNOR; Inhibitor of apoptosis; Ki 67; PCNA; Survivin

Indexed keywords

BIOLOGICAL MARKER; CELL NUCLEUS ANTIGEN; CYCLINE; INHIBITOR OF APOPTOSIS PROTEIN; NUCLEAR PROTEIN; NUCLEOLAR ORGANIZER REGION ASSOCIATED PROTEINS; TUMOR PROTEIN;

ANIMAL; ANIMAL DISEASE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; DOG; DOG DISEASE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; SARCOMA;

ANIMALS; ANTIGENS, NUCLEAR; APOPTOSIS; BIOLOGICAL MARKERS; CELL PROLIFERATION; DOG DISEASES; DOGS; GENE EXPRESSION REGULATION, NEOPLASTIC; INHIBITOR OF APOPTOSIS PROTEINS; MAST-CELL SARCOMA; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN;

CANIS FAMILIARIS;

EID: 32344434851     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2006)20[151:CMCTCO]2.0.CO;2     Document Type: Article

References (37)

1. Dobson JM, Samuel S, Milstein H, et al. Canine neoplasia in the UK: Estimates of incidence rates from a population of insured dogs. J Small Anim Pract 2002;43:240-246.
2. Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol 1984;21:469-474.
3. Seguin B, Leibman NF, Bregazzi VS, et al. Clinical outcome of dogs with grade-II mast cell tumors treated with surgery alone: 55 cases (1996-1999). J Am Vet Med Assoc 2001;218:1120-1123.
4. Weisse C, Shofer FS, Sorenmo K. Recurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision. J Am Anim Hosp Assoc 2002;38:71-73.
5. Murphy S, Sparkes AH, Smith KC, et al. Relationships between the histological grade of cutaneous mast cell tumours in dogs, their survival and the efficacy of surgical resection. Vet Rec 2004;154:743-746.
6. Simoes JP, Schoning P, Butine M. Prognosis of canine mast cell tumors: A comparison of three methods. Vet Pathol 1994;31: 637-647.
7. Bostock DE, Crocker J, Harris K, et al. Nucleolar organiser regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumours. Br J Cancer 1989;59:915-918.
8. Kravis LD, Vail DM, Kisseberth WC, Ogilvie GK, Volk LM. Frequency of argyrophilic nucleolar organizer regions in fineneedle aspirates and biopsy specimens from mast cell tumors in dogs. J Am Vet Med Assoc 1996;209:1418-1420.
9. Abadie JJ, Amardeilh MA, Delverdier ME. Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs. J Am Vet Med Assoc 1999;215:1629-1634.
10. Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): A dancer with many partners. J Cell Sci 2003;116:3051-3060.
11. Endl E, Gerdes J. The Ki-67 protein: Fascinating forms and an unknown function. Exp Cell Res 2000;257:231-237.
12. Schluter C, Duchrow M, Wohlenberg C, et al. The cell proliferation- associated antigen of antibody Ki-67: A very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 1993;123:513-522.
13. Roels S, Tilmant K, Ducatelle R. PCNA and Ki67 proliferation markers as criteria for prediction of clinical behaviour of melanocytic tumours in cats and dogs. J Comp Pathol 1999;121:13-24.
14. Laprie C, Abadie J, Amardeilh MF, et al. Detection of the Ki-67 proliferation associated nuclear epitope in normal canine tissues using the monoclonal antibody MIB-1. Anat Histol Embryol 1998;27:251-256.
15. Brown DC, Gatter KC. Ki67 protein: The immaculate deception? Histopathology 2002;40:2-11.
16. Pena LL, Nieto AI, Perez-Alenza D, et al. Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: Relationship to clinical and pathologic variables. J Vet Diagn Invest 1998;10:237-246.
17. Phillips BS, Kass PH, Naydan DK, et al. Apoptotic and proliferation indexes in canine lymphoma. J Vet Diagn Invest 2000;12:111-117.
18. Ferez Alenza MD, Pena L, del Castillo N, et al. Factors influencing the incidence and prognosis of canine mammary tumours. J Small Anim Pract 2000;41:287-291.
19. Laprie C, Abadie J, Amardeilh MF. et al. MIB-1 immunoreactivity correlates with biologic behaviour in canine cutaneous melanoma. Vet Dermatol 2001;12:139-147.
20. Labelle P, Kyles AE, Farver TB, et al. Indicators of malignancy of canine adrenocortical tumors: Histopathology and proliferation index. Vet Pathol 2004;41:490-497.
21. Destexhe E, Vanmanshoven P, Coignoul F. Comparison of argyrophilic nucleolar organizer regions by counting and image analysis in canine mammary tumors. Am J Vet Res 1995;56:185-187.
22. Johnson GC, Miller MA, Ramos-Vara JA. Comparison of argyrophilic nucleolar organizer regions (AgNORs) and mitotic index in distinguishing benign from malignant canine smooth muscle tumors and in separating inflammatory hyperplasia from neoplastic lesions of the urinary bladder mucosa. J Vet Diagn Invest 1995;7:127-136.
23. Kiupel M, Teske E, Bostock D. Prognostic factors for treated canine malignant lymphoma. Vet Pathol 1999;36:292-300.
24. Sarli G, Preziosi R, Benazzi C, et al. Prognostic value of histologic stage and proliferative activity in canine malignant mammary tumors. J Vet Diagn Invest 2002;14:25-34.
25. Ofner D, Schmid KW. Standardized AgNOR analysis: Its usefulness in surgical oncology. Histochem Cell Biol 1996;106:193-196.
26. Pich A, Chiusa L, Margaria E. Prognostic relevance of AgNORs in tumor pathology. Micron 2000;31:133-141.
27. Aubele M, Biesterfeld S, Derenzini M, et al. Guidelines of AgNOR quantitation: Committee on AgNOR Quantitation within the European Society of Pathology. Zentralbl Pathol 1994;140:107-108.
28. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921.
29. Kallio MJ, Nieminen M, Eriksson JE. Human inhibitor of apoptosis protein (IAP) survivin participates in regulation of chromosome segregation and mitotic exit. FASEB J 2001;15:2721-2723.
30. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004;4:592-603.
31. Adida C, Crotty PL, McGrath J, et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998;152:43-49.
32. Andersen MH, thor SP. Survivin: A universal tumor antigen. Histol Histopathol 2002;17:669-675.
33. Chakravarti A, Noll E, Black PM, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002;20:1063-1068.
34. Lo Muzio L, Pannone G, Leonardi R, et al. Survivin, a potential early predictor of tumor progression in the oral mucosa. J Dent Res 2003;82:923-928.
35. Trere D. AgNOR staining and quantification. Micron 2000; 31:127-131.
36. Therneau TG. Modeling Survival Data: Extending the Cox Model. New York: Springer Verlag; 2000:107-111.
37. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54.